Organization - Additional Information (Details) $ / shares in Units, $ in Thousands			3 Months Ended
	Feb. 09, 2021 USD ($) $ / shares shares	Jan. 28, 2021	Mar. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	[1]	Mar. 31, 2020 USD ($)
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Entity incorporation, date of incorporation			Feb. 20, 2013
Reverse stock split, description			On January 28, 2021, the Company’s board of directors approved a 1-for-4.3103 reverse stock split (the “Reverse Stock Split”) of the Company’s common stock and each series of its redeemable convertible preferred stock to be consummated prior to the effectiveness of the Company’s initial public offering (“IPO”) on February 4, 2021.
Stock split conversion ratio		0.2320
Proceeds from issuance of common stock on IPO, net of issuance costs			$ 160,092
Conversion of stock | shares	23,978,747
Cash			189,813	$ 58,212		$ 19,811
Accumulated deficit			(77,030)	$ (63,714)
Revenue from sale of test kits			$ 4,500
IPO | Common Stock
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Number of shares issued in transaction | shares	10,350,000
Shares issued price per share | $ / shares	$ 17.00
Proceeds from issuance of common stock on IPO, net of issuance costs	$ 159,900
Underwriting discounts and commissions	12,300
Offering expenses	$ 3,700
Conversion of stock | shares	25,449,694
Underwriters' Option to Purchase Additional Shares | Common Stock
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Number of shares issued in transaction | shares	1,350,000

[1] The balance sheet as of December 31, 2020 is derived from the audited financial statements as of that date